Get the Stockscreener App
13.07
1.55%
0.20
After Hours:
13.09
0.02
+0.15%
Replimune Group Inc stock is traded at $13.07, with a volume of 2.14M.
It is up +1.55% in the last 24 hours and down -16.11% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
See More
Previous Close:
$12.87
Open:
$13.02
24h Volume:
2.14M
Relative Volume:
0.48
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$-313.94M
P/E Ratio:
-3.7279
EPS:
-3.506
Net Cash Flow:
$-284.57M
1W Performance:
+1.16%
1M Performance:
-16.11%
6M Performance:
+93.34%
1Y Performance:
+277.75%
1-Day Range:
$12.68
$13.20
1-Week Range:
$12.46
$13.64
52-Week Range:
$1.50
$16.33
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
13.07 | 1.22B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| Apr-13-26 | Downgrade | H.C. Wainwright | Buy → Sell |
| Apr-13-26 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-13-26 | Downgrade | Jefferies | Buy → Hold |
| Apr-13-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-13-26 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-10-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Stocktwits
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Stock DropRobbins LLP Reminds Investors They May Be - GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class ActionContact Levi & Korsinsky - Business Wire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
REPL: TUDRIQEV launch targets rapid adoption in key accounts, with expansion and new indications ahead - TradingView
DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of - GlobeNewswire
Replimune faces class action over alleged nondi... - Pluang
Replimune at cantor healthcare conference: careful launch, broad pipeline By Investing.com - Investing.com Canada
REPL Investor Alert: Replimune Group, Inc. Securities Class Action NoticeContact SueWallSt - PR Newswire
Class action lawsuit filed against Replimune fo... - Pluang
Replimune faces securities lawsuit over alleged misleading FDA trial data claims, stock plunged 84%. - Pluang
REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Replimune Group Stock Short Interest Falls to 43.08% - moomoo.com
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Price to earnings forward of Replimune Group, Inc. – NASDAQ:REPL - TradingView
2026-09-06 | REPL SHAREHOLDER ALERT - Stockhouse
Avoiding Lag: Real-Time Signals in (REPL) Movement - Stock Traders Daily
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - Eastern Progress
Replimune shares plunge 84% after FDA rejects R... - Pluang
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders - GlobeNewswire
Replimune investors urged to seek lead plaintiff role by Oct 5 deadline - scanx.trade
Class action lawsuit filed against Replimune af... - pluang.com
REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Replimune to Present at the Cantor Global Healthcare Conference 2026 - The Manila Times
Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc. - Business Wire
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Morningstar
Replimune Group stock hits 52-week high at 16.2 USD By Investing.com - Investing.com Canada
Replimune Group stock hits 52-week high at 16.2 USD - Investing.com
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of - GlobeNewswire
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities LawsuitContact SueWallSt - PR Newswire
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Replimune Group stock hits 52-week high at 15.72 USD By Investing.com - Investing.com Nigeria
REPL Deadline Alert: Levi & Korsinsky Reminds Replimune - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - Eastern Progress
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop - TipRanks
Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action - PR Newswire
DEADLINE ALERT for BZAI, BABA, ALAR, and REPL: The Law - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? - Stocktwits
Replimune (REPL) Results at a Glance: Profit Per Share Falls Below Its Benchmark; Market Response: Shares Move Lower 3.31% in the Available RecordFinancial Summary - vinanet.vn
REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Chief Executive Officer |
Aug 10 '26 |
Sale |
12.97 |
39,341 |
510,253 |
708,151 |
| Hill Emily Luisa | Chief Financial Officer |
Aug 10 '26 |
Sale |
12.97 |
11,448 |
148,481 |
225,108 |
| Xynos Konstantinos | Chief Medical Officer |
Aug 10 '26 |
Sale |
12.97 |
11,447 |
148,468 |
224,215 |
| Schwendenman Andrew | Chief Accounting Officer |
Aug 10 '26 |
Sale |
12.97 |
7,632 |
98,987 |
99,425 |
| Sarchi Christopher | Chief Commercial Officer |
Jun 01 '26 |
Sale |
9.24 |
12,000 |
110,880 |
180,962 |
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):